{"filing":{"accession_number":"0001193125-26-248711","cik":"0001213037","ticker":"CRDF","company_name":"Cardiff Oncology, Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"crdf-20260527.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526248711/crdf-20260527.htm"},"events":[{"id":8141,"run_id":7146,"accession_number":"0001193125-26-248711","anchor_item_number":"1.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.75,"summary":"The filing discloses a material dispute between Cardiff Oncology and Nerviano Medical Sciences involving a license agreement termination and competing claims of material breach. Cardiff filed a lawsuit on May 19, 2026 seeking injunctive relief and declaratory judgment, and NMS responded with a termination notice on May 27, 2026 alleging breaches related to patent inventorship and failure to conduct development activities for onvansertib. While Item 1.01 nominally covers \"Entry into a Material Definitive Agreement,\" the substance here is a material litigation and contractual dispute that would significantly affect a reasonable investor's assessment of the company's rights to key intellectual property and product development obligations.","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-05-29","submitted_at":null,"items":[{"id":2743,"accession_number":"0001193125-26-248711","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material dispute between Cardiff Oncology and Nerviano Medical Sciences involving a license agreement termination and competing claims of material breach. Cardiff filed a lawsuit on May 19, 2026 seeking injunctive relief and declaratory judgment, and NMS responded with a termination notice on May 27, 2026 alleging breaches related to patent inventorship and failure to conduct development activities for onvansertib. While Item 1.01 nominally covers \"Entry into a Material Definitive Agreement,\" the substance here is a material litigation and contractual dispute that would significantly affect a reasonable investor's assessment of the company's rights to key intellectual property and product development obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:15:34.372422+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2743,"accession_number":"0001193125-26-248711","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material dispute between Cardiff Oncology and Nerviano Medical Sciences involving a license agreement termination and competing claims of material breach. Cardiff filed a lawsuit on May 19, 2026 seeking injunctive relief and declaratory judgment, and NMS responded with a termination notice on May 27, 2026 alleging breaches related to patent inventorship and failure to conduct development activities for onvansertib. While Item 1.01 nominally covers \"Entry into a Material Definitive Agreement,\" the substance here is a material litigation and contractual dispute that would significantly affect a reasonable investor's assessment of the company's rights to key intellectual property and product development obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:15:34.372422+00:00","company_name":"Cardiff Oncology, Inc.","ticker":"CRDF","filing_date":"2026-05-29"}]}